Alan Goodman has been appointed to the supervisory board of the German biopharmaceutical company, Paion AG, effective 31 July 2008. Mr Goodman is a chartered management accountant and the founder of CeNeS Pharmaceuticals Plc, which was acquired by Paion in June. He is also founder and chief executive officer of Avlar BioVentures, a venture capital fund that invests in early-stage life science companies.
Mr Goodman succeeds Professor Dr Erich Schlick who resigned from Paion’s board on 30 July due to his responsibilities as general partner at another venture capital company.
Copyright 2008 Evernow Publishing Ltd